InflaRx N.V. Restores Compliance with Nasdaq Regulations
InflaRx N.V., a biopharmaceutical pioneer, has proudly announced its successful compliance with the Nasdaq minimum bid price requirement, a significant milestone for the company. This compliance was confirmed through a recent notice from The Nasdaq Stock Market's Listing Qualifications Department, affirming that InflaRx has met the necessary standards.
Understanding Nasdaq's Minimum Bid Price Requirement
The Nasdaq minimum bid price requirement stipulates that a company must maintain a closing bid price of at least $1.00 per share for a designated period. InflaRx achieved this milestone by having its ordinary shares demonstrate a closing price of $1.00 or above for a commendable ten consecutive business days. This achievement was noted from late August to early September, indicating a strong market presence.
Performance Insights
This notable performance suggests a recovery and stability in the stock's performance, which is essential for maintaining investor confidence and enhancing market visibility. Regaining compliance is not merely a regulatory achievement; it reflects positively on the company’s strategic actions and operational health.
The Importance of C5a Inhibitors
InflaRx N.V. is at the forefront of developing innovative anti-inflammatory therapeutics, specifically targeting the complement system. The company focuses on harnessing its unique anti-C5a and anti-C5a receptor technologies to devise specific inhibitors aimed at controlling complement activation. C5a plays a crucial role as an inflammatory mediator, influencing numerous inflammatory conditions.
Vilobelimab: A Game-Changer in Treatment
Among InflaRx’s most promising developments is vilobelimab, a first-in-class anti-C5a monoclonal antibody. This revolutionary treatment is administered intravenously and selectively binds to free C5a, demonstrating significant clinical activity across various trials. This innovative approach holds the potential to modify the disease processes in multiple inflammatory conditions, showcasing the therapeutic promise InflaRx brings to the medical community.
Company Background and Operations
Established in 2007, InflaRx N.V. has created a robust presence in the biopharmaceutical landscape. With headquarters in Germany and an operational base in the US, it has a dedicated team focused on addressing pressing healthcare needs through pioneering research and development. Its commitment to innovation underlines its overarching mission to enhance patient outcomes.
Global Reach and Future Endeavors
InflaRx operates through fully owned subsidiaries located in Jena and Munich, Germany, and Ann Arbor, MI, USA. This global footprint allows for a diverse approach to developing and commercializing new therapies. Looking forward, the company continues to explore the potential of its current portfolio and expand its reach within the industry, ensuring they remain leaders in the field of anti-inflammatory therapeutics.
Company Contacts
For further inquiries, InflaRx is reachable through its investor relations team:
InflaRx N.V.
Jan Medina, CFA
Vice President, Head of Investor Relations
Email: IR@inflarx.de
MC Services AG
Katja Arnold, Laurie Doyle, Dr. Regina Lutz
Email: inflarx@mc-services.eu
Europe: +49 89-210 2280
U.S.: +1-339-832-0752
Frequently Asked Questions
What signifies InflaRx's compliance with Nasdaq?
InflaRx regained compliance by maintaining a closing bid price of at least $1.00 for ten consecutive business days.
What does the minimum bid price requirement entail?
The minimum bid price requirement mandates a listing company to maintain a stock price above $1.00 for continued listing on Nasdaq.
What is vilobelimab?
Vilobelimab is an anti-C5a monoclonal antibody developed by InflaRx, designed to treat various inflammatory diseases with significant clinical application.
Where is InflaRx headquartered?
InflaRx is headquartered in Germany, with additional operations in the United States.
Who can I contact for more information about InflaRx?
You can contact their investor relations team via email at IR@inflarx.de or through their contact at MC Services AG.
